From: Predicting disease-free survival in colorectal cancer by circulating tumor DNA methylation markers
Characteristic | Training group | Validation group | P |
---|---|---|---|
N | 84 | 56 | Â |
Gender, n (%) | Â | Â | 0.916 |
Female | 35 (25%) | 22 (15.7%) | Â |
Male | 49 (35%) | 34 (24.3%) | Â |
BMIÂ (kg/m2), n (%) | Â | Â | 1.000 |
18.5–23.9 | 46 (32.9%) | 31 (22.1%) |  |
≥24, or <18.5 | 38 (27.1%) | 25 (17.9%) |  |
CEAÂ (ug/L), n (%) | Â | Â | 0.683 |
≤ 100 | 81 (57.9%) | 53 (37.9%) |  |
>Â 100 | 3 (2.1%) | 3 (2.1%) | Â |
CA199Â (U/mL), n (%) | Â | Â | 0.626 |
≤37 | 73 (52.1%) | 51 (36.4%) |  |
>37 | 11 (7.9%) | 5 (3.6%) | Â |
pT, n (%) | Â | Â | 0.219 |
T1 | 14 (10%) | 8 (5.7%) | Â |
T2 | 19 (13.6%) | 14 (10%) | Â |
T3 | 42 (30%) | 33 (23.6%) | Â |
T4 | 9 (6.4%) | 1 (0.7%) | Â |
pN, n (%) | Â | Â | 0.071 |
N0 | 66 (47.1%) | 37 (26.4%) | Â |
N1 | 11 (7.9%) | 16 (11.4%) | Â |
N2 | 7 (5%) | 3 (2.1%) | Â |
pTNM, n (%) | Â | Â | 0.229 |
Stage I | 32 (22.9%) | 16 (11.4%) | Â |
Stage II | 34 (24.3%) | 21 (15%) | Â |
Stage III | 18 (12.9%) | 19 (13.6%) | Â |
Age (years), mean ± SD | 59.39 ± 11.22 | 60.5 ± 9.69 | 0.535 |